Is There Enhanced Risk of Cerebral Ischemic Stroke by Sulfonylureas in Type 2 Diabetes?

Hyperglycemia enhances stroke injury in humans and experimental animals, and type 2 diabetes mellitus (T2DM) is a known risk factor for stroke. Sulfonylurea (SU) drugs have been used for over six decades for management of T2DM; they exhibit their principal antidiabetes property by inhibiting KATP channels and promoting an increase in insulin secretion by pancreatic b-cells (1,2) (Fig. 1A). The KATP channel in the pancreas is a complex of four subunits of the KCNJ11 gene product Kir6.2 and four subunits of the ABCC8 gene product SUR1 (3). SU drugs bind to SUR1 to block the KATP channel. Although treatment of T2DM reduces stroke risk, the study by Liu et al. (4) in this issue of Diabetes addresses the question of whether SU drugs can enhance stroke risk and stroke injury by inhibiting KATP channels in brain. The study makes three points. First, a 5-day administration of streptozotocin (STZ) to mice led to persistent hyperglycemia (blood glucose .16 mmol/L) and decreased body weight (,10% from controls); following a 90-min transient middle cerebral artery occlusion (MCAO), infarct size and neurological deficit were both significantly greater in mice given STZ. Second, in cortical mouse neurons subjected to oxygen-glucose deprivation and in normoglycemic mice subjected to permanent MCAO, neuronal cell death and stroke injury were increased with the SU tolbutamide but decreased with the KATP channel opener diazoxide. Third, a meta-analysis of human clinical trials in patients with T2DM was performed. Seventeen randomized controlled trials, with a combined total of over 27,000 patients, that compared SUs to placebo or other antidiabetes drugs and reported stroke incidence were included. The analysis revealed a .30% increase in the incidence of stroke in patients treated with SUs. Thus, this report concludes that SU drugs increase stroke risk and are used in a patient population that is already at greater risk of stroke (4). The study by Liu et al. supports the findings of a previous study by the senior authors, which reported increased stroke injury using transient MCAO in Kir6.2 knockout mice relative to wild-type mice (5). However, there are other reports describing beneficial effects of SU drugs in rodent models of cerebral ischemia (6–8). Interestingly, in the brain, SUR1 serves as a regulatory subunit for both the KATP channel and a nonselective cation channel, NCCa-ATP (9). The pore-forming subunit of the NCCa-ATP channel was recently identified as Trpm4 (10). The NCCa-ATP channel conducts monovalent cations, is activated by depletion of cellular ATP, and requires nanomolar concentrations of Ca for opening (11). Thus, ischemic conditions are reported to trigger opening of both KATP and NCCa-ATP channels, but whereas KATP channel opening is hyperpolarizing, NCCa-ATP channel opening is depolarizing (Fig. 1B). In rodent models of cerebral stroke, it was demonstrated that blockage of newly expressed SUR1 in ischemic neurons, astrocytes, and capillaries with a low dose of the SU glibenclamide reduced cerebral edema, infarct volume, and mortality by 50%, and this was associated with cortical sparing (8). Simard et al. (8) hypothesized that the NCCa-ATP channel is crucially involved in development of cerebral edema and that targeting SUR1 may provide a new therapeutic approach to stroke. Another study reported beneficial effects of glibenclamide in a rat global forebrain ischemia-reperfusion model; antioxidant and anti-inflammatory effects, rather than KATP or NCCa-ATP channel activities, were observed (6). Resolving these differences should provide important information for the basic science of stroke pathology, stroke treatment, and the pharmacology of SU drugs. In principle, the beneficial/detrimental effects of individual SU drugs could be due to 1) differing affinities for SUR1 in association with Kir6.2 versus Trpm4, 2) differing affinities for non-SUR1 targets, 3) differing blood-brain barrier permeability or drug trapping within ischemic brain tissue, and/or 4) differences between stroke models and animal species among research laboratories.